Manufacturer of Controlled Substances; Notice of Registration, 43454-43455 [05-14831]
Download as PDF
<![CDATA[
43454
Federal Register / Vol. 70, No. 143 / Wednesday, July 27, 2005 / Notices
in the amount of $28.25 (25 cents per
page reproduction cost) payable to the
U.S. Treasury.
and enclose a check in the amount of
$7.50 (25 cents per page reproduction
costs), payable to the U.S. Treasury.
Catherine McCabe,
Deputy Section Chief, Environmental
Enforcement Section, Environment and
Natural Resources Division.
[FR Doc. 05–14891 Filed 7–26–05; 8:45 am]
Robert E. Maher, Jr.,
Ass’t Chief, Environmental Enforcement
Section, Environment and Natural Resources
Division.
[FR Doc. 05–14890 Filed 7–26–05; 8:45 am]
BILLING CODE 4410–15–M
BILLING CODE 4410–15–M
DEPARTMENT OF JUSTICE
DEPARTMENT OF JUSTICE
Notice of Lodging of Consent Decree
Pursuant to the Comprehensive
Environmental Response,
Compensation, and Liability Act
Drug Enforcement Administration
In accordance with Departmental
policy, 28 CFR 50.7, notice is hereby
given that a proposed consent decree in
United States v. Murray Pacific Corp.,
Civil Action No. CO5–5473FDB, was
lodged on July 19, 2005, with the United
States District Court for the Western
District of Washington. The consent
decree requires defendants Murray
Pacific Corp., Boardman Brown and
Mary Jane Anderson, to compensate
natural resource trustees for natural
resource damages in Commencement
Bay, Washington, resulting from
releases of hazardous substances. The
trustees are the State of Washington, the
Puyallup Tribe of Indians, the
Muckleshoot Indian Tribe, the National
Oceanic and Atmospheric
Administration of the United States
Department of Commerce, and the
United States Department of the
Interior. Under the consent decree,
defendants will pay $302,00 for natural
resource damages and assessment costs.
The Department of Justice will
receive, for a period of thirty (30) days
from the date of this publication,
comments relating to the proposed
consent decree. Comments should be
addressed to the Assistant Attorney
General for the Environment and
Natural Resources Division, Department
of Justice, Washington, DC 20530, and
should refer to United States v. Murray
Pacific Corp., DOJ Ref. #90–11–2–1049.
The proposed consent decree may be
examined at the office of the United
States Attorney, 601 Union Street,
Seattle, WA 98101. During the public
comment period, the Consent Decree
may be examined on the following
Department of Justice Web site: https://
www.usdoj.gov/enrd/open.html, and at
the Consent Decree Library, PO Box
7611, U.S. Department of Justice,
Washington, DC 20044–7611 or by
faxing a request to Tonia Fleetwood, fax
no. (202) 514–0097, phone confirmation
number (202) 514–1547. In requesting a
copy please refer to the referenced case
By Notice dated February 23, 2005,
and published in the Federal Register
on March 4, 2005, (70 FR 10683), Sigma
Aldrich Research Biochemicals, Inc.,
1–3 Strathmore Road, Natick,
Massachusetts 01760, made application
by letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the basic classes
of controlled substances listed in
Schedules I and II:
VerDate jul<14>2003
19:40 Jul 26, 2005
Jkt 205001
Manufacturer of Controlled
Substances; Notice of Registration
Drug
Schedule
Cathinone (1235) ..........................
Methcathinone (1237) ..................
Aminorex (1585) ...........................
Alpha-ethyltryptamine (7249) .......
Lysergic acid diethylamide (7315)
Tetrahydrocannabinols (7370) .....
4-Bromo-2,5-dimethoxy-amphetamine (7391).
4-Bromo-2,5dimethoxyphenethylamine
(7392).
2,5-Dimethoxyamphetamine
(7396).
3,4-Methylenedioxyamphetamine
(7400).
N-Hydroxy-3,4-methylenedioxyamphetamine (7402).
3,4-Methylenedioxy-Nethylamphetamine (7404).
3,4-Methylenedioxymethamphetamine (MDMA) (7405).
1-[1-(2-Thienyl)cyclohexyl]piperidine (TCP) (7470).
Heroin (9200) ...............................
Normorphine (9313) .....................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
1-Phenylcyclohexylamine (7460)
Phencyclidine (7471) ....................
Cocaine (9041) .............................
Codeine (9050) .............................
Diprenorphine (9058) ...................
Ecgonine (9180) ...........................
Levomethorphan (9210) ...............
Levorphanol (9220) ......................
Meperidine (9230) ........................
Metazocine (9240) ........................
Methadone (9250) ........................
Morphine (9300) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
I
I
I
I
I
I
I
Drug
Carfentanil (9743) .........................
Fentanyl (9801) ............................
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for laboratory reference standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Sigma Aldrich Research Biochemicals,
Inc. to manufacture the listed basic
classes of controlled substances is
consistent with the public interest at
this time. DEA has investigated Sigma
Aldrich Research Biochemicals, Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–14834 Filed 7–26–05; 8:45 am]
I
BILLING CODE 4410–09–P
I
DEPARTMENT OF JUSTICE
I
Drug Enforcement Administration
I
Manufacturer of Controlled
Substances; Notice of Registration
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
By Notice dated February 17, 2005,
and published in the Federal Register
on February 28, 2005, (70 FR 9677),
Boehringer Ingelheim Chemical Inc.,
2820 N. Normandy Drive, Petersburg,
Virginia 23805, made application by
letter to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of
Tetrahydrocannabinols (7370), a basic
class of controlled substance listed in
Schedule I.
The company plans to manufacture
the listed controlled substance in bulk
for use in analysis and drug test
standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of
Boehringer Ingelheim Chemical Inc. to
E:\FR\FM\27JYN1.SGM
27JYN1
43455
Federal Register / Vol. 70, No. 143 / Wednesday, July 27, 2005 / Notices
manufacture the listed basic class of
controlled substance is consistent with
the public interest at this time. DEA has
investigated Boehringer Ingelheim
Chemical Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic classes of controlled
substances listed.
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–14831 Filed 7–26–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration
By Notice dated April 11, 2005 and
published in the Federal Register on
April 20, 2005 (70 FR 20600), Clinical
Trial Services (US), Inc., 2661 Audubon
Road, Audubon, Pennsylvania 19403,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as an importer of
Fentanyl (9801), a basic class of
controlled substance listed in Schedule
II.
The company plans to import small
quantities of the listed controlled
substance in dosage form to conduct
clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a)
and determined that the registration of
Clinical Trial Services (US), Inc. to
import the basic class of controlled
substance is consistent with the public
interest and with United States
obligations under international treaties,
conventions, or protocols in effect on
May 1, 1971, at this time. DEA has
investigated Clinical Trial Services (US),
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
VerDate jul<14>2003
19:40 Jul 26, 2005
Jkt 205001
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–14825 Filed 7–26–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By Notice dated February 23, 2005,
and published in the Federal Register
on March 4, 2005, (70 FR 10679), JFC
Technologies, LLC, 100 West Main
Street, Bound Brook, New Jersey 08805,
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic class of
controlled substances listed in Schedule
II:
Drug
Schedule
Diphenoxylate (9170) ...................
Hydrocodone (9193) .....................
II
II
The company plans to manufacture
the listed controlled substances in bulk
for distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of JFC
Technologies, LLC to manufacture the
listed basic class of controlled
substances is consistent with the public
interest at this time. DEA has
investigated JFC Technologies, LLC to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substances
listed.
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–14836 Filed 7–26–05; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration
By notice dated February 23, 2005,
and published in the Federal Register
on March 4, 2005 (70 FR 10680), Lin Zhi
International Inc., 687 North Pastoria
Avenue, Sunnyvale, California 94085
made application by renewal to the
Drug Enforcement Administration
(DEA) to be registered as a bulk
manufacturer of the basic class of
controlled substances listed in Schedule
II:
Drug
Oxycodone (9143) ........................
Hydrocodone (9193) .....................
Schedule
II
II
The company plans to manufacture
the listed controlled substances in bulk
for use in analysis and drug test
standards.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and
determined that the registration of Lin
Zhi International Inc. to manufacture
the listed basic class of controlled
substances is consistent with the public
interest at this time. DEA has
investigated Lin Zhi International Inc. to
ensure that the company’s registration is
consistent with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 823,
and in accordance with 21 CFR 1301.33,
the above named company is granted
registration as a bulk manufacturer of
the basic class of controlled substances
listed.
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 05–14828 Filed 7–26–05; 8:45 am]
BILLING CODE 4410–09–P
E:\FR\FM\27JYN1.SGM
27JYN1
]]>Agencies
[Federal Register Volume 70, Number 143 (Wednesday, July 27, 2005)]
[NOTIC]
[Pages 43454-43455]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-14831]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Registration
By Notice dated February 17, 2005, and published in the Federal
Register on February 28, 2005, (70 FR 9677), Boehringer Ingelheim
Chemical Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made
application by letter to the Drug Enforcement Administration (DEA) to
be registered as a bulk manufacturer of Tetrahydrocannabinols (7370), a
basic class of controlled substance listed in Schedule I.
The company plans to manufacture the listed controlled substance in
bulk for use in analysis and drug test standards.
No comments or objections have been received. DEA has considered
the factors in 21 U.S.C. 823(a) and determined that the registration of
Boehringer Ingelheim Chemical Inc. to
[[Page 43455]]
manufacture the listed basic class of controlled substance is
consistent with the public interest at this time. DEA has investigated
Boehringer Ingelheim Chemical Inc. to ensure that the company's
registration is consistent with the public interest. The investigation
has included inspection and testing of the company's physical security
systems, verification of the company's compliance with state and local
laws, and a review of the company's background and history. Therefore,
pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, the
above named company is granted registration as a bulk manufacturer of
the basic classes of controlled substances listed.
Dated: July 19, 2005.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug
Enforcement Administration.
[FR Doc. 05-14831 Filed 7-26-05; 8:45 am]
BILLING CODE 4410-09-P
